Bristol-Myers-Squibb announces acquisition deal
Pharmaceutical company Bristol-Myers Squibb (BMS) has agreed a deal that gives it the option of acquiring drug maker F-star Alpha and one of its breast and gastric cancer treatments.
The agreement, announced today (October 28), may see BMS acquire the right to F-star’s FS102, which treats human epidermal growth factor receptor 2 (HER2) type cancer.
The technology, which is ready for phase, provides treatment of breast and gastric cancer among HER2-positive patients who do not respond or become resistant to current therapies.
Under the agreement, BMS will make payments of around $50 million to F-star that include the option to acquire the company in full, as well to assume the rights and licences related to FS102 and a clinical milestone payment after a phase 1 trial begins.
According to BMS, it still has the option to acquire F-star Alpha in its entirety if it decides to commence a phase 2b trial.
The total terms of the deal may reach $475 million.
Francis Cuss, executive vice president and chief scientific officer at BMS, said the agreement was consistent with its R&D strategy to develop promising treatments that address areas of high unmet medical need.
“We look forward to working with F-star and leveraging our broad clinical expertise in oncology to uncover the full potential of FS102,” Cuss added.
John Haurum, chief executive at F-star, said the company was “thrilled”.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk